LBRX

LB Pharmaceuticals Inc

39.70

Oct 30 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: MPLT ANRO ACAD NMRA AXSM VNDA SPTX HELP RLMD MNOV

| Held by: VTI IWM VXF XPH SCHA VTWO IWN IWO IHE IWC

Index	RUT
Market Cap	1.28B
Enterprise Value	958.12M
Income	-85.69M
Sales	0.00M
Book/sh	11.59
Cash/sh	10.16
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	27
IPO	Sep 11, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.43
P/C	3.91
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	15.08
Current Ratio	15.08
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-2.98
EPS next Y	-5.32
EPS next Q	-1.62
EPS this Y	-80.48%
EPS next Y	5.89%
EPS next 5Y	-20.74%
EPS past 3/5Y	-15.94% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-132.05%
Sales Y/Y TTM	-
EPS Q/Q	-689.03%
Sales Q/Q	-
Earnings	Aug 11 BMO
EPS/Sales Surpr.	-112.77% -

Insider Own	25.84%
Insider Trans	0.00%
Inst Own	83.72%
Inst Trans	7.80%
ROA	-14.55%
ROE	-15.70%
ROIC	-25.45%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	6.03%
SMA50	-4.05%
SMA200	21.87%
Trades

Shs Outstand	28.68M
Shs Float	23.92M
Short Float	23.26%
Short Ratio	15.14
Short Interest	5.56M
52W High	50.16 -20.85%
52W Low	14.32 177.30%
Volatility	5.11% 6.50%
ATR (14)	2.26
RSI (14)	52.93
Beta	0.82
Rel Volume	0.00
Avg Volume	367.61K
Volume	0

Perf Week	2.50%
Perf Month	6.49%
Perf Quarter	-7.33%
Perf Half Y	26.31%
Perf YTD	78.35%
Perf Year	143.86%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.17
Target Price	58.92
Prev Close	39.70
Price	39.70
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$58.92

Implied Upside

+48.4%

Analysts11incl. previous ratings

Rating Distribution10 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 09, 2026	Initiated	CCanaccord Genuity	Buy	$65	+63.7%
Oct 06, 2026	Initiated	GGuggenheim	Buy	$80	+101.5%
Oct 05, 2026	Downgrade	RRoth Capital	Buy → Neutral	$35	-11.8%
Oct 02, 2026	Initiated	NNeedham	Buy	$68	+71.3%
Jul 21, 2026	Initiated	BBMO Capital Markets	Outperform	$46	+15.9%
Jul 07, 2026	Initiated	WWolfe Research	Outperform	$45	+13.4%
Apr 27, 2026	Initiated	HH.C. Wainwright	Buy	$45	+13.4%
Apr 10, 2026	Initiated	CCraig Hallum	Buy	$36	-9.3%
Jan 09, 2026	Initiated	RRoth Capital	Buy
Oct 06, 2025	Initiated	SStifel	Buy	$27	-32.0%
Oct 06, 2025	Initiated	PPiper Sandler	Overweight	$78	+96.5%
Oct 06, 2025	Initiated	LLeerink Partners	Outperform	$34	-14.4%

Oct-28-26 06:40PM	Guggenheim names LB Pharmaceuticals a top idea ahead of pivotal trial data (Investing.com)
Oct-15-26 04:05PM	LB Pharmaceuticals to Participate in Upcoming Investor Events (GlobeNewswire) +7.91%
Oct-10-26 08:00AM	LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102's Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress (GlobeNewswire)
Oct-09-26 04:42PM	LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.54%
Oct-06-26 08:00AM	LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB-102 with a Focus on Schizophrenia Treatment (GlobeNewswire)
08:00AM	Loading…
Sep-15-26 08:00AM	LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer (GlobeNewswire)
Sep-09-26 08:02AM	IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target? (Investor's Business Daily)
Sep-03-26 04:05PM	LB Pharmaceuticals to Participate in Upcoming September Investor Events (GlobeNewswire)
08:00AM	LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer (GlobeNewswire)
Aug-11-26 08:07AM	LB Pharmaceuticals Inc.: Q2 Earnings Snapshot (Associated Press)
08:00AM	LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-29-26 08:00AM	LB Pharmaceuticals Announces $150 Million Private Placement (GlobeNewswire) +11.62%
Jul-22-26 08:00AM	LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia (GlobeNewswire) +10.93%
Jul-21-26 09:40AM	Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls (The Fly)
Jul-10-26 04:38PM	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Jun-30-26 08:00AM	LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations (GlobeNewswire)
May-28-26 04:05PM	LB Pharmaceuticals to Participate in Upcoming June Investor Events (GlobeNewswire)
May-12-26 04:15PM	LB Pharmaceuticals Inc.: Q1 Earnings Snapshot (Associated Press)
04:05PM	LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-22-26 04:05PM	LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia (GlobeNewswire)
Apr-09-26 04:05PM	LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.42%
Mar-27-26 12:00PM	LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) (GlobeNewswire)
Mar-26-26 04:21PM	LB Pharmaceuticals Inc.: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-25-26 08:00AM	LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia (GlobeNewswire)
Mar-09-26 08:00AM	LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors (GlobeNewswire)
Mar-04-26 04:05PM	LB Pharmaceuticals to Participate in Upcoming March Investor Events (GlobeNewswire)
Feb-27-26 11:44AM	Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments (PR Newswire)
Feb-10-26 04:41PM	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-26 08:00AM	LB Pharmaceuticals Announces $100.0 Million Private Placement (GlobeNewswire) +12.71%
08:06AM	Loading…
Jan-27-26 08:06AM	LB Pharmaceuticals initiates Phase 2 trial of LB-102 (TipRanks)
Jan-26-26 08:00AM	LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program (GlobeNewswire) -6.40%
Jan-21-26 08:00AM	LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel (GlobeNewswire)
Jan-12-26 04:05PM	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.20%
Jan-06-26 07:00AM	LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture (GlobeNewswire)
Dec-10-25 05:04PM	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.29%
Dec-09-25 08:00AM	LB Pharmaceuticals Added to the Russell 2000 and Russell 3000 Indices (GlobeNewswire)
Nov-24-25 08:00AM	LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire) +5.28%
Nov-12-25 04:15PM	LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.63%
08:00AM	LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer (GlobeNewswire)
Nov-06-25 04:05PM	LB Pharmaceuticals Announces Presentation at the Stifel 2025 Healthcare Conference (GlobeNewswire)
08:12AM	LB Pharmaceuticals Inc.: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates (GlobeNewswire)
Oct-14-25 08:30AM	LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs (GlobeNewswire)
Oct-06-25 08:30AM	LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms (GlobeNewswire)
Sep-25-25 08:30AM	LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani (GlobeNewswire)
Sep-12-25 04:27PM	Crunching the numbers on this week's IPO performances (Yahoo Finance Video)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PRENSKY ZACHARY	Former Officer	Jun 09 '26	Proposed Sale	29.49	16,500	486,566		Jun 09 05:41 PM

LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its product pipeline includes LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The company was founded by Vince Grattan and Zachary Prensky in 2015 and is headquartered in New York.

J.D.Ms. Heather D. Turner Esq.

Chief Operating & Business OfficerMr. Gad Soffer

Ph.D.Ms. Minako Pazdera J.D.

Senior VP of People & CultureMs. Lindsay Beaupre

Senior Vice President of Technical OperationsDr. Richard A. Silva Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LBRX

LB Pharmaceuticals Inc

Upgrade your Finviz experience